The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
The effect of long-term proactive or reactive treatment of psoriasis with calcipotriene and betamethasone dipropionate (Cal/BD) foam via patient-reported outcomes is reported.
Among biologics used for the treatment of psoriasis, there do not appear to be differential risks for serious infection or respiratory tract infection.
The extent to which tofacitinib affects the health-related quality of life in patients with psoriatic arthritis was studied, based on improvements in itch.
Researchers examined the association between psoriasis severity and the development of psoriatic arthritis.
Antihypertensive drugs are associated with an increased risk for psoriasis.
An extension analysis of a study of patients with psoriasis treated with risankizumab is reported.
The short- and long-term effectiveness of brodalumab in patients with psoriasis in whom treatment with IL-17A inhibitors has failed is examined.
The risk for serious infection in patients with psoriasis treated with biologic agents and apremilast, using etanercept as a comparator, is examined.